StockData

Autolus Therapeutics vs Coherus Oncology

AUTL and CHRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AUTL and CHRS compare

Autolus Therapeutics is the larger company, worth 3.9 times as much as Coherus Oncology ($290M against $73.9M).

Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 61.0% for Coherus Oncology).

Autolus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −239% compared with −259% at Coherus Oncology.

Coherus Oncology scores higher on the StockData Score (7 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUTLCHRS
Size and price
Market cap$290M$73.9M
Share price$1.09$0.478
Change, 1 year−20.4%−59.8%
Change, 5 years−82.6%−97.4%
Beta (5Y)3.470.88
Employees754147
StockData Score
Total score57 (better)
Valuation score13 (better)
Growth score3 (better)2
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/S2.5×1.5× (better)
P/B3.9×1.2× (better)
FCF yield−80.2%–
Fair value$1.36$1.16
Margin of safety19.8%58.8% (better)
Growth
Revenue growth (TTM)292% (better)61.0%
Revenue growth, 5Y average–−38.4%
Net income growth (TTM)–−174%
EPS growth, 5Y average–−2.5%
Profitability
Gross margin15.7%68.9% (better)
Operating margin−211% (better)−312%
Net margin−239% (better)−259%
FCF margin−198%–
Return on equity−133% (better)−146%
Financial health
Interest coverage−5.9× (better)−17.5×
Current ratio4.89 (better)1.77
Altman Z-score−4.60 (better)−12.33
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions49.7%45.5%
Held by insiders24.6%1.3%
Insider net buying, 12 months−$15.7K–
Short interest, % of float–8.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.